LH — Labcorp Holdings Inc.

Labcorp Holdings Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $3.5 billion, up 6% year-over-year.
• Adjusted Earnings Per Share (EPS): $4.25, an increase of 10.6%.
• Adjusted Operating Margin: 14.4%, improved by over 30 basis points.
• Free Cash Flow: $71 million, compared to a cash use of $108 million in Q1 2025.
• Diagnostics Revenue: $2.8 billion, up 5% with 3.1% organic growth.
• Biopharma Laboratory Services Revenue: $781 million, up 8.2%, with 3.7% organic growth.

2. Strategic Updates and Business Highlights

• Partnerships: Announced a collaboration with Children's Hospital of Philadelphia to enhance pediatric diagnostics.
• Acquisitions: Completed acquisition of Crouse Health's laboratory assets and are on track to acquire outreach laboratory services from Parkview Health.
• Specialty Testing Growth: Significant growth in neurology and oncology, with double-digit increases driven by new tests and expanded access.
• Consumer Health Initiatives: Launched new tests and the MyLabcorp mobile app, enhancing consumer engagement and driving double-digit growth in Labcorp OnDemand.
• Technology Integration: Expanded use of AI and robotics to improve operational efficiency and customer experience.

3. Forward Guidance and Outlook

• Revenue Growth Forecast: Enterprise revenue expected to grow 5% to 6.1% for 2026, with Diagnostics segment growth forecasted at 5.1% to 5.9%.
• Adjusted EPS Guidance: Range of $17.70 to $18.35, implying a growth rate of approximately 10% at the midpoint.
• Free Cash Flow Projection: Expected to be between $1.24 billion and $1.36 billion for the full year.

4. Bad News, Challenges, or Points of Concern

• Weather Impact: Estimated $15 million revenue impact from adverse weather conditions in Q1; organic volume growth would have been approximately 2% higher without this impact.
• ACA Exchange Uncertainty: Potential headwinds from changes in ACA enrollment and testing utilization, with an estimated 30 basis point impact on diagnostic volumes for the year.
• Regulatory Risks: Concerns regarding the CRUSH initiative from CMS aimed at reducing fraud and waste, which could affect access to laboratory testing.
• Early Development Business: Flat growth in Early Development segment, with ongoing strategic actions expected to complete by the end of Q2.

5. Notable Q&A Insights

• Volume Trends: Management indicated that weather affected volume growth, with a recovery strategy in place for missed appointments.
• Bookings in Biopharma Laboratory Services: Strong growth in Central Labs, with expectations for sequential improvement in book-to-bill ratios.
• Consumer Testing Environment: Continued investment in consumer health initiatives, with a focus on high-margin specialty areas.
• PAMA Survey Participation: Anticipated impact of PAMA on Labcorp dependent on hospital participation in reporting, with ongoing advocacy for the RESULTS Act to ensure fair implementation.

Overall, Labcorp demonstrated strong financial performance in Q1 2026, with significant growth in key areas and strategic initiatives aimed at enhancing its market position, while also facing challenges related to weather impacts, regulatory changes, and potential shifts in consumer behavior.